278 related articles for article (PubMed ID: 36897017)
1. Repurposing of the antibiotic nitroxoline for the treatment of mpox.
Bojkova D; Zöller N; Tietgen M; Steinhorst K; Bechtel M; Rothenburger T; Kandler JD; Schneider J; Corman VM; Ciesek S; Rabenau HF; Wass MN; Kippenberger S; Göttig S; Michaelis M; Cinatl J
J Med Virol; 2023 Mar; 95(3):e28652. PubMed ID: 36897017
[TBL] [Abstract][Full Text] [Related]
2. Clinical considerations on monkeypox antiviral medications: An overview.
Pourkarim F; Entezari-Maleki T
Pharmacol Res Perspect; 2024 Feb; 12(1):e01164. PubMed ID: 38149674
[TBL] [Abstract][Full Text] [Related]
3. The discovery of novel antivirals for the treatment of mpox: is drug repurposing the answer?
Ezat AA; Abduljalil JM; Elghareib AM; Samir A; Elfiky AA
Expert Opin Drug Discov; 2023 May; 18(5):551-561. PubMed ID: 37032577
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf.
De Clercq E; Jiang Y; Li G
Travel Med Infect Dis; 2023; 52():102528. PubMed ID: 36539022
[TBL] [Abstract][Full Text] [Related]
5. Antivirals With Activity Against Mpox: A Clinically Oriented Review.
Siegrist EA; Sassine J
Clin Infect Dis; 2023 Jan; 76(1):155-164. PubMed ID: 35904001
[TBL] [Abstract][Full Text] [Related]
6. Emerging pharmacological strategies for treating and preventing mpox.
Grosenbach DW; Russo AT; Blum ED; Hruby DE
Expert Rev Clin Pharmacol; 2023; 16(9):843-854. PubMed ID: 37592723
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis.
Shamim MA; Satapathy P; Padhi BK; Veeramachaneni SD; Akhtar N; Pradhan A; Agrawal A; Dwivedi P; Mohanty A; Pradhan KB; Kabir R; Rabaan AA; Alotaibi J; Al Ismail ZA; Alsoliabi ZA; Al Fraij A; Sah R; Rodriguez-Morales AJ
Front Pharmacol; 2023; 14():1149909. PubMed ID: 37214444
[TBL] [Abstract][Full Text] [Related]
8. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023.
Smith TG; Gigante CM; Wynn NT; Matheny A; Davidson W; Yang Y; Condori RE; O'Connell K; Kovar L; Williams TL; Yu YC; Petersen BW; Baird N; Lowe D; Li Y; Satheshkumar PS; Hutson CL
Emerg Infect Dis; 2023 Dec; 29(12):2426-2432. PubMed ID: 37856204
[TBL] [Abstract][Full Text] [Related]
9. Potential therapeutic targets for Mpox: the evidence to date.
Byrareddy SN; Sharma K; Sachdev S; Reddy AS; Acharya A; Klaustermeier KM; Lorson CL; Singh K
Expert Opin Ther Targets; 2023; 27(6):419-431. PubMed ID: 37368464
[TBL] [Abstract][Full Text] [Related]
10. Challenges in Managing Treatment-Resistant Mpox Complicated by Severe Superinfection.
Fortier JC; Marsalisi C; Cordova E; Guo HJ; Verdecia J
Open Forum Infect Dis; 2024 Apr; 11(4):ofae138. PubMed ID: 38651138
[TBL] [Abstract][Full Text] [Related]
11. Antivirals for the treatment of Monkeypox: utilization in the general and HIV-positive population and gaps for research. A short narrative review.
Ivanov DT; Slabakova YA; Argirova RM; Valkov TK
Infez Med; 2023; 31(2):186-194. PubMed ID: 37283638
[TBL] [Abstract][Full Text] [Related]
12. Lack of clinical evidence of antiviral therapy for human monkeypox: A scoping review.
Kuroda N; Shimizu T; Hirano D; Ishikane M; Kataoka Y
J Infect Chemother; 2023 Feb; 29(2):228-231. PubMed ID: 36283609
[TBL] [Abstract][Full Text] [Related]
13. Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments.
Akazawa D; Ohashi H; Hishiki T; Morita T; Iwanami S; Kim KS; Jeong YD; Park ES; Kataoka M; Shionoya K; Mifune J; Tsuchimoto K; Ojima S; Azam AH; Nakajima S; Park H; Yoshikawa T; Shimojima M; Kiga K; Iwami S; Maeda K; Suzuki T; Ebihara H; Takahashi Y; Watashi K
J Infect Dis; 2023 Aug; 228(5):591-603. PubMed ID: 36892247
[TBL] [Abstract][Full Text] [Related]
14. Mpox (monkeypox): Diagnosis, prevention, and management in adults.
Jarrell L; Perryman K
Nurse Pract; 2023 Apr; 48(4):13-20. PubMed ID: 36975744
[TBL] [Abstract][Full Text] [Related]
15. Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies.
Rabaan AA; Abas AH; Tallei TE; Al-Zaher MA; Al-Sheef NM; Fatimawali ; Al-Nass EZ; Al-Ebrahim EA; Effendi Y; Idroes R; Alhabib MF; Al-Fheid HA; Adam AA; Bin Emran T
J Med Virol; 2023 Jan; 95(1):e28306. PubMed ID: 36372558
[TBL] [Abstract][Full Text] [Related]
16. Antivirals against Monkeypox (Mpox) in Humans: An Updated Narrative Review.
Bruno G; Buccoliero GB
Life (Basel); 2023 Sep; 13(10):. PubMed ID: 37895350
[TBL] [Abstract][Full Text] [Related]
17. Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents.
Hishiki T; Morita T; Akazawa D; Ohashi H; Park ES; Kataoka M; Mifune J; Shionoya K; Tsuchimoto K; Ojima S; Azam AH; Nakajima S; Kawahara M; Yoshikawa T; Shimojima M; Kiga K; Maeda K; Suzuki T; Ebihara H; Takahashi Y; Watashi K
Microbiol Spectr; 2023 Aug; 11(4):e0056623. PubMed ID: 37409948
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in the Prevention and Management of Monkeypox Viral Infection in Humans.
Gujjar P; Chaudhay R; Verma I; Bansal N; Gupta S; Bansal S
Curr Drug Targets; 2023; 24(13):1032-1045. PubMed ID: 37842888
[TBL] [Abstract][Full Text] [Related]
19. Preventing monkeypox outbreaks: Focus on diagnosis, care, treatment, and vaccination.
Ghaseminia M
J Clin Transl Sci; 2023; 7(1):e60. PubMed ID: 37008622
[TBL] [Abstract][Full Text] [Related]
20. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review.
Shamim MA; Padhi BK; Satapathy P; Veeramachaneni SD; Chatterjee C; Tripathy S; Akhtar N; Pradhan A; Dwivedi P; Mohanty A; Rodriguez-Morales AJ; Sah R; Al-Tammemi AB; Al-Tawfiq JA; Nowrouzi-Kia B; Chattu VK
Int J Infect Dis; 2023 Feb; 127():150-161. PubMed ID: 36470502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
